Cargando…

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)

Detalles Bibliográficos
Autores principales:	Reeves, Barnaby C, Underwood, Wendy, Cappel-Porter, Heike, Baos, Sarah, Rogers, Chris A, Arnott, Michael, Harding, Simon P, Chakravarthy, Usha, Foss, Alex E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287704/ http://dx.doi.org/10.1186/1745-6215-12-S1-A13

Ejemplares similares

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
por: Batioglu, Figen, et al.
Publicado: (2015)

Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
por: Reid, Christopher A., et al.
Publicado: (2018)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial
por: Evans, Rebecca N., et al.
Publicado: (2020)

Epimacular brachytherapy for wet AMD: current perspectives
por: Casaroli-Marano, Ricardo P, et al.
Publicado: (2014)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania
por: Stanca, Horia T., et al.
Publicado: (2019)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Aqueous humor cytokine profiling in patients with wet AMD
por: Liu, Fang, et al.
Publicado: (2016)

Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis
por: Ba, Jun, et al.
Publicado: (2015)

Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
por: Giancipoli, Ermete, et al.
Publicado: (2018)

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
por: Varano, Monica, et al.
Publicado: (2015)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
por: Lüke, Jan Niklas, et al.
Publicado: (2022)

Expression of VEGFA‐regulating miRNAs and mortality in wet AMD
por: Blasiak, Janusz, et al.
Publicado: (2019)

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD
por: Tognetto, Daniele, et al.
Publicado: (2011)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab
por: Dikmetas, Ozlem, et al.
Publicado: (2013)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial
por: Neffendorf, James E., et al.
Publicado: (2016)

Intravitreal Combination of Dexamethasone Sodium Phosphate and Bevacizumab in The Treatment of Exudative AMD
por: Vakalis, N., et al.
Publicado: (2015)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination
por: Courtaut, Flavie, et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015)

PGE(2) promotes macrophage recruitment and neovascularization in murine wet-type AMD models
por: Zhan, Pengfei, et al.
Publicado: (2022)

Single-Cell Transcriptome of Wet AMD Patient-Derived Endothelial Cells in Angiogenic Sprouting
por: Yeo, Natalie Jia Ying, et al.
Publicado: (2022)

The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano, Monica, et al.
Publicado: (2016)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g0pvmrhigpiiv804rs49iipe84